



July 7, 2007 04:47 PM US Eastern Standard Time

Capricor Receives Benediction at Papal Review of Adult Stem Cells

Baltimore, Maryland. – July 7, 2007. Capricor Inc. (www.capricor.com), participated in a scientific mission to the Vatican as part of the invited scientific seminar entitled *Cardiac Stem Cells: What We Need For Clinical Translation*, sponsored by the University of Rome La Sapienza and held June 27-28 at the Antonino and Faustina Temple.

Capricor as well as a number of academic groups took part and were received in the Vatican pilgrims hall, where Pope Benedict XVI issued the following address as reported in ZENIT News agency.

=====
ZENIT, The world seen from Rome
News Agency
=====

Benedict XVI Encourages Adult Stem Cell Research The Pope said this today to a group of experts who attended the general audience in Paul VI Hall. The scientists, many of whom are doctors, are gathered in an international conference dedicated to adult stem cell research, organized by the University of Rome La Sapienza. The Holy Father approved their objective of developing therapies with adult stem cells, since in this case "the dignity of the human person is respected," given that human embryos are neither eliminated nor made the subjects of experimentation. "In this sense, the position of the Church, supported by reason and science, is clear: Scientific investigation should be justly encouraged and promoted, on the condition that it is not in detriment to other human beings."

=====
ZE07062709
2007-06-27
=====

This article is from the ZENIT news agency.

Capricor Inc., located in Baltimore, Maryland, is a leading biotechnology company that specializes in discovering, developing, and commercializing biotherapeutics for the treatment of heart diseases. Capricor's mission is to revolutionize the treatment of cardiac disease by translating novel stem cell science into therapeutics that halt and reverse the disease process for patient's, their families, and society in general.

***Translating today's cardiac research innovations
into tomorrow's heart therapies***